Atrasentan high dose group — Competitive Intelligence Brief

Atrasentan high dose group (Atrasentan high dose group) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Endothelin receptor antagonist. Area: Cardiovascular.

phase 2 Endothelin receptor antagonist Endothelin receptor Cardiovascular Small molecule

Target snapshot

Atrasentan high dose group (Atrasentan high dose group) — AbbVie (prior sponsor, Abbott). Atrasentan is an endothelin receptor antagonist that blocks the action of endothelin-1, a potent vasoconstrictor.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Atrasentan high dose group TARGET	Atrasentan high dose group	AbbVie (prior sponsor, Abbott)	phase 2	Endothelin receptor antagonist	Endothelin receptor
Tracleer®	Tracleer®	Actelion	marketed	Endothelin receptor antagonist	Endothelin receptor A (ETA) and Endothelin receptor B (ETB)
"Nefecon®","Ambrisentan"	"Nefecon®","Ambrisentan"	The First Hospital of Jilin University	marketed	Endothelin receptor antagonist (ERA)	Endothelin receptor type A (ETA)
EFI/ACT-385781A	EFI/ACT-385781A	Actelion	phase 3	Selective endothelin receptor antagonist	Endothelin receptor (ETA/ETB)
Duo-Therapy with Sildenafil + Bosentan	Duo-Therapy with Sildenafil + Bosentan	Johns Hopkins University	phase 3	Combination therapy: phosphodiesterase-5 inhibitor + endothelin receptor antagonist	PDE-5; Endothelin receptor A and B
Bosentan and Sildenafil	Bosentan and Sildenafil	Rigshospitalet, Denmark	phase 3	Endothelin receptor antagonist and phosphodiesterase-5 inhibitor combination	Endothelin receptors (ETA/ETB) and phosphodiesterase-5
FDC macitentan/tadalafil	FDC macitentan/tadalafil	Actelion	phase 3	Endothelin receptor antagonist / Phosphodiesterase-5 inhibitor combination	Endothelin receptor A and B / Phosphodiesterase-5

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Endothelin receptor antagonist class)

1. AbbVie (prior sponsor, Abbott) · 2 drugs in this class
2. Actelion · 2 drugs in this class
3. Bayer · 1 drug in this class
4. Dr Sudarshan Rajagopal · 1 drug in this class
5. Eli Lilly and Company · 1 drug in this class
6. Elpen Pharmaceutical Co. Inc. · 1 drug in this class
7. National Heart, Lung, and Blood Institute (NHLBI) · 1 drug in this class